Lipocine Receives Updated Regulatory Guidance on LPCN 1154 - PR Newswire
2025-02-06 • Google News
Lipocine Inc (LPCN)
US$ 4.76-14.85%
Price Chart
Key Statistics
Market Cap
$ 16.96M
P/E Ratio
0.00
Revenue (TTM)
$ 3.67M
Volume
66.66K
52W High
$ 7.18
52W Low
$ 2.68
Dividend Yield
0.00%
Beta
1.33
Technicals
50-Day MA
3.2944
200-Day MA
4.0507
52 Week High
7.18
52 Week Low
2.6838
About LPCN
Lipocine Inc., a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders.
Employees
16
Headquarters
Salt Lake City, UT
CEO
Dr. Mahesh V. Patel Ph.D.
Latest News
Top Gainers
Symbol/Name
LTP
% Chg
Top Losers
Symbol/Name
LTP
% Chg